If you still have questions as to whether or not you might ever consistently outperform the market, MoneyShow’s Howard R. Gold has compiled some research results that, he feels, will give you some answers.
Year after year, decade after decade, evidence has piled up that neither individual nor professional investors can outperform broad market indexes consistently over long periods of time.
Studies of fund managers, active traders, and other institutional investors have failed to find persistent outperformance that wasn’t caused by either luck or being in the right part of the market at the right time.
Eugene Fama of the University of Chicago, who won a Nobel Prize in economics last week, pioneered the efficient market theory that said stock prices incorporated all relevant information available to investors.
I always thought that theory went too far—individual stocks and whole asset classes can remain mispriced for years, as Fama’s fellow Nobel winner, Robert Shiller of Yale University, has shown.
Top 5 Dow Dividend Stocks To Buy For 2015: XOMA Ltd.(XOMA)
XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. Its products under development include gevokizumab, an anti-inflammatory monoclonal antibody that inhibits interleukin-1 beta and has completed Phase 2 development stage for the treatment of Behcet?s uveitis, as well as is in Phase 2b clinical trail for Type 2 diabetes with cardiovascular biomarkers; XOMA 3AB, a biodefense anti-botulism product candidate comprising a combination or cocktail of antibodies for the treatment of botulism poisoning; and preclinical antibody discovery programs in various indications, including autoimmune, cardio-metabolic, inflammatory, and oncological diseases. The company, through its collaboration agreement with Novartis AG, is also developing HCD122, a human anti-CD40 antagonist antibody that is in Phase 1/2 clinical trial for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases; and LFA102, which is in Phase 2 clinical trial for the treatment of hematologic tumors and other undisclosed diseases. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; SRI International; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; Genentech, Inc.; and UCB Celltech. XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California.
- [By Jake L’Ecuyer]
Equities Trading DOWN
Shares of XOMA (NASDAQ: XOMA) were down 27.54 percent to $6.84 after the company reported Q4 results and provided anupdate on its gevokizumab development program. Credit Suisse downgraded the stock from Outperform to Neutral.
- [By John Kell and Lauren Pollock var popups = dojo.query(“.socialByline .popC”); ]
XOMA Corp.(XOMA) said it swung to a loss in the fourth quarter, as an increase in operating expenses offset revenue gains. The drug developer’s losses were wider than expected by the market, sending shares down 20% to $7.54 premarket.
- [By Lisa Levin]
XOMA (NASDAQ: XOMA) shares reached a new 52-week high of $8.61. XOMA shares have jumped 196.09% over the past 52 weeks, while the S&P 500 index has gained 25.27% in the same period.
Top 5 Dow Dividend Stocks To Buy For 2015: King George Financial Corp (KGF)
King George Financial Corporation is a Canada-based company. The Company operates in the area of commercial and residential real estate investment holding and development, as well as medium to long term investment in real estate and hotel related marketable securities. The Company has four segments: rental operation, real estate development, management and finance services, and others. Its principle assets include an office building in downtown Vancouver, British Columbia, held through its 100% subsidiary 905 W. Pender Investments Ltd; real estate located in the City of Surrey, British Columbia, held through its subsidiary 0819277 BC Ltd, 0788607 BC Ltd, and 50% ownership interest in Surrey Campus Residences Joint Venture. The real estate assets consist of residential building lots, and investment in common shares of Allied Hotel Properties Inc., a hotel ownership and management company, and United Malayan Land BHD (UML), a Malaysian real estate development company. Advisors’ Opinion:
- [By Sofia Horta e Costa]
Kingfisher Plc (KGF) declined 5.7 percent to 373.6 pence, its biggest loss in more than two years, after Chief Executive Officer Ian Cheshire said consumer confidence in France “is still weak with no obvious signs of an imminent improvement.” Europe’s largest home-improvement retailer also reported same-store sales growth of 0.4 percent for its B&Q chain in the U.K. and Ireland, missing analysts’ estimates. France accounted for about 40 percent of its sales and the U.K. for 41 percent, data compiled by Bloomberg showed.
Top 5 Dow Dividend Stocks To Buy For 2015: WiLan Inc (WILN)
WiLAN Inc. (WiLAN), incorporated on May 14, 1992, is a licensing company. WiLAN develops, acquires, and licenses a range of intellectual property that drives products in communications and consumer electronics markets. Through both internal research and development and acquisitions from third parties, the Company has acquired intellectual property in the form of patents and patent applications in many countries that it has licensed to more than 255 companies in telecommunications markets around the world. As of December 31, 2011, WiLAN had a portfolio of approximately 3,000 patents, including issued and pending patents and foreign equivalents. WiLAN has five directly wholly-owned subsidiaries, Wi-LAN Capital Inc. (WiLAN Capital), Wi-LAN International Inc. (WiLAN International), Wi-LAN International Hong Kong Inc. (WiLAN Hong Kong), Wi-LAN International Japan Inc. (WiLAN Japan) and Wi-LAN International Taiwan Inc. In July 2012, it acquired a global portfolio of more than 40 patents and applications from Siemens AG related to telecommunication network management and mobile multimedia. In October 2012, the Company acquired a global portfolio of more than 150 patents and patent applications from Alvarion Ltd. In June 2013, WiLan Inc acquired a portfolio of patents from Cypress Semiconductor Corporation. In November 2013, the Company acquired a portfolio of semiconductor patents from IXYS CH GmbH related to microcontroller technology.
In the Company’s licensing business, the Company has signed licenses with companies that sell products utilizing technologies, including CDMA (Code Division Multiple Access-a cellular telecommunications specification); Wi-Fi (the underlying technology of wireless local area networks based on various IEEE 802.11 specifications); WiMAX (Worldwide Interoperability for Microwave Access-a standards-based broadband wireless technology that provides metropolitan area network connectivity based on IEEE 802.16 sp ecifications); LTE (Long Term Evolution-high performance air! interface for cellular mobile communication systems designed to increase the capacity and speed of mobile telephone networks), and ADSL (Asymmetric Digital Subscriber Line-a standards-based access technology that provides broadband Internet access over twisted pair telecommunications wiring). The Company has also signed licenses with companies that sell products utilizing technologies, including DOCSIS (Data Over Cable Service Interface Specifications-a standards-based access technology that provides broadband Internet access over cable networks); Bluetooth (a wireless protocol for exchanging data over short distances between fixed and mobile devices), and V-Chip (a technology that permits the blocking of television programs at a receiver (such as a television, multi-media equipped personal computer or set-top box) by viewers based on ratings information carried on the television signal).
- [By Monica Gerson]
Wi-LAN (NASDAQ: WILN) today announced that its Board of Directors has initiated a process to explore and evaluate a broad range of strategic alternatives for the Company to enhance shareholder value. To read the full news, click here. MannKind (NASDAQ: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for AFREZZA® (insulin human [rDNA origin]) Inhalation Powder. To read the full news, click here. lululemon athletica (NASDAQ: LULU) today announced that Tara Poseley has been appointed to its Senior Leadership Team as Chief Product Officer. To read the full news, click here. Nice Systems (NASDAQ: NICE) reported a drop in its third-quarter profit. To read the full news, click here.
Posted-In: Bank of America FOMC US Stock FuturesNews Eurozone Futures Pre-Market Outlook Markets
- [By Rich Duprey]
Often accused of being a patent troll, non-performing entity WiLAN (NASDAQ: WILN ) wrangled a settlement out of Dell (NASDAQ: DELL ) with details of the deal remaining confidential.
Top 5 Dow Dividend Stocks To Buy For 2015: Tellabs Inc.(TLAB)
Tellabs, Inc. designs, develops, and supports telecommunications networking products for communication service providers in the United States and internationally. Its products and services enable customers to deliver wireless and wireline voice, data, and video services to business and residential customers. The company operates through three segments: Broadband, Transport, and Services. The Broadband segment provides access products that enable service providers to deliver bundled voice, video, and high-speed Internet/data services over copper or fiber networks; managed access products, which deliver wireless and business services primarily outside of North America; and data products, including packet-switched products that enable wireless and wireline carriers to deliver mobile voice and Internet services, and wireline business services to their customers. The Transport segment enables service providers to manage network bandwidth by adding capacity needed; and wireline and wireless providers to support metro networks, mobile services, and business services for enterprises, as well as triple-play voice, video, and data services for residential consumers. The Services segment delivers deployment, training, support, and professional services, which support various phases of the network, such as planning, building, and operating. Tellabs, Inc. serves primarily communication services providers, including local exchange carriers; wireline and wireless service providers; multiple system operators; competitive service providers; distributors; original equipment manufacturers; system integrators; and government agencies. The company sells its products and services through its direct sales and sales support personnel, value-added resellers, independent sales representatives, distributors, and public and private network providers. Tellabs, Inc. was founded in 1974 and is headquartered in Naperville, Illinois.
- [By Rick Munarriz]
Tellabs (NASDAQ: TLAB ) checks in on Thursday. The provider of mobile backhaul, packet optical, and services solutions to communications services lost its CEO to colon cancer last year. It has also lost its mojo. Wall Street sees Tellabs merely breaking even in 2013 on a 14% decline in revenue.
- [By Selena Maranjian]
The biggest new holdings are Seagate Technology and Warner Chilcott. Other new holdings of interest include Tellabs (NASDAQ: TLAB ) and Windstream (NASDAQ: WIN ) . Tellabs offers a satisfying dividend yield of 3.7%, but the networking equipment maker has been facing some headwinds, such as the death of its CEO and the recent departure of its CFO. Its performance has been spotty, besting estimates in its fourth quarter but disappointing them in the recent first quarter.
- [By Rich Smith]
You have to hand it to Tellabs (NASDAQ: TLAB ) — they work fast.
Late last month, the networking equipment maker had to scramble when its acting chief financial officer, Tom Minichiello, announced plans to retire on July 12 to become the new CFO at Westell Technologies (NASDAQ: WSTL ) . On Friday, though, just as the deadline was happening, Tellabs announced that it has found a replacement.
Top 5 Dow Dividend Stocks To Buy For 2015: Express Scripts Holding Co (ESRX)
Express Scripts Holding Company, incorporated in 2011, provides healthcare management and administration services on behalf of its clients, which include health maintenance organizations (HMOs), health insurers, third-party administrators, employers, union-sponsored benefit plans, workers compensation plans, and government health programs. The Company operates in two segments: Pharmacy Benefit Management (PBM) and Emerging Markets (EM). PBM services include network claims processing, home delivery services, patient care and direct specialty and fertility home delivery to patients, benefit plan design consultation, drug utilization review, formulary management, drug data analysis services, distribution of injectable drugs to patients homes and physicians offices, bio-pharma services, and fulfillment of prescriptions to low-income patients through manufacturer-sponsored patient assistance programs. EM segment provides distribution of pharmaceuticals and medical supplies to p roviders and clinics, healthcare account administration and implementation of consumer-directed healthcare solutions. In September 2013, it announced the acquisition of the SmartD Medicare Prescription Drug Plan (PDP).
On July 20, 2011, Express Scripts, Inc. (ESI) entered into a merger agreement (the Merger Agreement) with Medco Health Solutions, Inc. (Medco). During the year ended December 31, 2011, it reorganized its FreedomFP line of business from its EM segment into its PBM segment. On April 2, 2012, the Company completed the Merger Agreement, and after which ESI and Medco became the wholly owned subsidiaries of the Company. The Company’s customers include HMOs, health insurers, third-party administrators, employers, union-sponsored benefit plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists and others.
- [By Ben Levisohn]
Gilead was pilloried again yesterday for developing a drug (Sovaldi) with the highest efficacy and fewest side effects, but at a high (but not the highest) price for a new HCV therapy. The cost-benefit ratio suggests it is not the most expensive therapy in the HCV space. While the politics of Washington are not surprising, the fact that a pharmacy distribution company [Express Scripts (ESRX)] would make what we consider to be political statements is damaging to the industry and patients they serve. They, better than us, understand the benefits of Sovaldi. We view these statements as noise and believe that Sovaldi and next-generation Ledipasvir/Sovaldi represent real pharmaco (economic) value in the HCV space.
- [By Ben Levisohn]
Gilead Sciences (GILD) has dropped 1% to $71.48 on reports that Express Scripts (ESRX) wants the biotech giant to lower the price of its hepatitis C drug, Sovaldi. Express Scripts has gained 0.6% to $73.16.